"We did not do prenatal genetic testing," said Rachel Hamm, who was in her late 20s when she became pregnant ... Treating children with Down syndrome for the myriad conditions that affect them often ...

Myriad Genetics ( (MYGN) ) has released its Q3 earnings. Here is a breakdown of the information Myriad Genetics presented to its investors.

Myriad Genetics delivers strong third-quarter results, driven by growth within Pharmacogenomics and Prenatal. The company ...

Third quarter revenue grew 11% year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) and ...

Global Cardiovascular Genetic Testing Market is valued at approximately USD 9.07 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 11.2% over the forecast period ...